Sirtex sees sales of SIR-Spheres ascend
Monday, 11 April, 2011
Sirtex (ASX:SRX) saw its stock bump by 2.5% to $5.45 in afternoon trading after announcing this morning that it has experienced its 27th consecutive quarter of dose sales growth of its anti-liver cancer treatment, SIR-Spheres.
Dose sales of the targeted radioactive treatment grew 20.7% for the quarter ending 31 March 2011 compared to the same quarter last year.
Year-to-date dose sales were up 18%, compared to 14.7% for the first three quarters of FY2010.
The fastest-growing market was Europe, up 23% compared to the same quarter last year, with US sales up 20% and Asia Pacific up 13%.
Revenue for FY2010 was $64.3 million, with a market cap of $304 million as of today.
The company posted a net profit of $3.6 million for the first half of FY2011, which is down 61% year-on-year due to the strong Australian dollar and increased costs, including higher prices from ANSTO of radiopharmaceuticals.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
